<article id="references_references" class="slide" data-ag-name="Slide 0">
	<h1 data-ag-editable="Title of the slide">参考文献</h1>
	<div id="references" class="wrapper">
		<ul>
			<li><a data-pdf="Wallentin PLATO- NEJM pivotal.pdf" data-ag-editable="Title pdf1"><span>1.</span>
				Wallentin L, Becker RC, Budaj A, et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. <i>N Engl J Med.</i> 2009;361(11):1045-1057. </a>
			</li>
			<li><a data-pdf="Wiviott 2007 NEJM TRITON.pdf" data-ag-editable="Title pdf2"><span>2.</span>
				Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndrome. <i>N Engl J Med. 2007;</i>357(20):2001-2015. </a>
			</li>
			<li><a data-pdf="ESC NSTE ACS guidelines 2011 update.pdf" data-ag-editable="Title pdf3"><span>3.</span>
				Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the managient of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the managient of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). <i>Eur Heart J.</i> 2011;32(23):2999-3054. </a>
			</li>
			<li><a data-pdf="Coughlin 2000 Nature thrombin.pdf" data-ag-editable="Title pdf4"><span>4.</span>
				Coughlin SR. Thrombin signaling and protease-activated receptors. <i>Nature.</i> 2000;407(680 1 ):258-264. </a>
			</li>
			<li><a data-pdf="Merlini circ 1994 thrombin_acs.pdf" data-ag-editable="Title pdf5"><span>5.</span>
				Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. <i>Circulation.</i> 1994;90(1):61-68. </a>
			</li>
			<li><a data-pdf="Mega_NEJM_2012.pdf" data-ag-editable="Title pdf6"><span>6.</span>
				Mega JL, Braunwald E, Wiviott SD, et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. <i>N Engl J Med.</i> 2012;366(1):9-19. </a>
			</li>
			<li><a data-pdf="Xarelto-SPC_2012-November.pdf" data-ag-editable="Title pdf7"><span>7.</span>
				Xarelto [placeholder for summary of product characteristics, 2.5 mg tablet]. Berlin, Germany: Bayer Pharma AG; November 2012. </a>
			</li>
			<li><a data-pdf="Steg-ESC-STEMI_2012.pdf" data-ag-editable="Title pdf8"><span>8.</span>
				Steg PG, James SK, Atar D, et al; ESC Committee for Practice Guidelines. ESC Guidelines for the managient of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the managient of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). <i>Eur Heart J.</i> 2012;33(20):2569-2619. </a>
			</li>
		</ul>
	</div>
	<div class="scroll-indicator">
	</div>
</article>